Evolus Inc. (EOLS)

31.77 -0.89 (-2.725%)

IEX Real-Time Price

June 20, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 32.66

Price Open 33.3

Volume: 500,000

Avg Volume: 768,209

Market Cap: 751.06M

P/E Ratio -

52 Wk Range 6.75-39.5



EOLS Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-05-31
23.64M
1.72M
2.61
7.29%

2018-05-15
23.64M
1.02M
4.67
4.32%

2018-04-30
23.64M
702,692
7.48
2.97%

2018-04-13
23.64M
640,079
4.91
2.71%




EOLS Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-10
Q1 2018
N/A
-0.36 (1)
-0.30
0.06

2018-03-29
Q4 2017
N/A
0.00 (0)
0.24
0.00

News

Evolus: Botox Competitor Poised For Massive Growth (2018-06-20 07:21 SeekingAlpha)

Evolus ( EOLS ) is a medical aesthetics company with the first 900 kDA botulinum toxin (DWP-450) since Botox. The Company has already demonstrated non-inferiority to Botox in several Phase 3 trials. Due to the fact that Evolus is only targeting the aesthetics market (and not the therapeutic…

 


Statistics

Shares Outstanding: 23.64M

Top 15 Institution Percent: 17.10

Price To Sales: N/A

Price To Book: 12.85

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -5.22

Return On Equity: -12.78

Profit Margin: N/A

Price History

Beta: 30.98

50-day Moving Avg: 16.78

200-day Moving Avg: N/A

YTD Change: 184.00

5-day Change: 16.81

1-month Change: 101.85

3-month Change: 171.26

6-month Change: 184.00

1-year Change: 184.00

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Evolus Inc.

Exchange: NASDAQ Global Market

Industry: Drug Manufacturers

Sector: Healthcare

Website: https://www.evolus.com

Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.